UNITY Biotechnology Revenue and Competitors
Estimated Revenue & Valuation
- UNITY Biotechnology's estimated annual revenue is currently $14.3M per year.
- UNITY Biotechnology received $55.0M in venture funding in March 2018.
- UNITY Biotechnology's estimated revenue per employee is $233,770
- UNITY Biotechnology's total funding is $290.6M.
- UNITY Biotechnology's current valuation is $84.3M. (January 2022)
Employee Data
- UNITY Biotechnology has 61 Employees.
- UNITY Biotechnology grew their employee count by -25% last year.
UNITY Biotechnology Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.7M | 61 | 9% | $53M | N/A |
#2 | $34.3M | 177 | 17% | $110M | N/A |
#3 | $0.4M | 273 | 5% | $236.7M | N/A |
#4 | $34.5M | 178 | -5% | $160M | N/A |
#5 | $3.7M | 24 | 20% | N/A | N/A |
#6 | $147.3M | 321 | 2% | $192.5M | N/A |
#7 | $17.5M | 113 | -3% | $24.1M | N/A |
#8 | $2.7M | 43 | 79% | N/A | N/A |
#9 | $34.1M | 220 | 100% | N/A | N/A |
#10 | $47.1M | 304 | -3% | N/A | N/A |
What Is UNITY Biotechnology?
UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com.
keywords:N/A
$290.6M
Total Funding
61
Number of Employees
$14.3M
Revenue (est)
-25%
Employee Growth %
$84.3M
Valuation
N/A
Accelerator
UNITY Biotechnology News
SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company...
UNITY Biotechnology to Present Clinical Data at the Association for Research in Vision & Ophthalmology (ARVO) 2022 Annual Meeting.
(UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the...
SUZHOU, China, and ROCKVILLE, Md., July 28, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its global licensee, UNITY Biotechnology, I ...
SUZHOU, China, and ROCKVILLE, Md., July 28, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its global licensee, UNITY Biotechnology, ...
Other Companies in Brisbane
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.7M | 61 | 49% | $16M |
#2 | $8.9M | 61 | 24% | N/A |
#3 | $8.4M | 62 | 22% | N/A |
#4 | $7.8M | 62 | 68% | N/A |
#5 | $15.1M | 62 | 38% | N/A |
UNITY Biotechnology Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-10-28 | $116.0M | B | Article | |
| 2017-08-18 | $35.0M | B | Multiple | Article |
| 2018-03-20 | $55.0M | C | EcoR1 Capital Fund | Article |
UNITY Biotechnology Executives
| Name | Title |
|---|---|
| Kathy Whalen | Executive Assitant to CFO and General Counsel |
| Lynne Sullivan | Chief Financial Officer |
| Jamie Dananberg | Chief Medical Officer |
| Catherine Torres | Executive Assistant To Chief Executive Officer |
| Mike Sapieha | Chief Scientific Advisor |
| Anirvan Ghosh | CEO |
| Susan Lundeen | SVP of People |
| Carl Millward | Vice President, Translational Medicine |
| Nathan Guz | Vice President |
| Derek Ragusa | Vice President, Development, Head of Product Team Leadership |
| Janet Martineau | Vice President, Head of Intellectual Property |
| Ben Hsu | VP, Clinical Development |
| Nathan Guz | Vice President of Operations |
